PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 31, 2026Journal of Korean Society of Health-System PharmacistsOpen Access

Evaluation of the Appropriateness, Efficacy, and Safety of Lurbinectedin in Patients with Metastatic Small Cell Lung Cancer : A Single-center Retrospective Study

View Full Paper
Ask AI
Bookmark
Share

Authors

SOSeung Min OhYKYe Seul KimSYSa Mi Yang

Discussion

Loading...

Member takes

Overview

Retrospective study evaluates lurbinectedin efficacy and safety in metastatic small cell lung cancer, suggesting potential benefits.

Key Points

  • The aim is to evaluate the appropriateness, efficacy, and safety of lurbinectedin in patients with metastatic small cell lung cancer.
  • Retrospective review of electronic medical records for patients treated with lurbinectedin from June 2023 to March 2024.
  • Assessment of prescription appropriateness according to regulatory guidelines.
  • Efficacy and safety endpoints included progression-free survival, overall survival, objective response rate, and adverse events.
  • 98 prescriptions were issued to 30 patients, with 83.7% adhering to approved dosing.
  • Median progression-free survival was 2.76 months (95% CI: 2.29-3.23), and median overall survival was 8.12 months (95% CI not specified).
  • Anemia (100%), hypoalbuminemia (76.7%), and lymphopenia (60.0%) were the most common adverse events recorded.

Cite This Study

Oh et al. (2026) studied this question.

synapsesocial.com/papers/6a1bcfb05783ba022b6fbb39https://doi.org/10.32429/jkshp.2026.43.2.003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes with lurbinectedin in second-line and beyond for small cell lung cancer in Korea.2024 · 1 citations
  2. 2A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer2024 · 10 citations
  3. 3Outcomes of Lurbinectedin in Central Nervous System Metastases of Small Cell Lung Cancer: A Single-Institution Retrospective Case Series2026
  4. 4Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme2024 · 7 citations
  5. 5Real-world safety and healthcare resource utilization (HCRU) of lurbinectedin (lurbi) in patients (pts) with small cell lung cancer (SCLC): Jazz EMERGE 402 updated analysis.2024 · 1 citations